Browsing by Author "Tombak, Anil"

Now showing 1 - 4 of 4

Association Between Pon1 L55m Polymorphism and Pon1 Enzyme Activity in Patients With Leukemia
(Akad Doktorlar Yayinevi, 2017) Eras, Nazan; Tombak, Anil; Tiftik, Naci; Yalin, Serap; Berkoz, Mehmet; Kul, Seval; Akbas, Etem
Paraoxonase 1 (PON1) is an important antioxidant enzyme which has a role in preventing the effects of systemic oxidative stress. The purpose of our study was to investigate the possible association between PON1 L55M polymorphism and leukemia development and to determine the relationship between PON1 genotypes and PON1 enzyme activities. Genotypes of 102 cases and 112 healthy controls were determined by PCR-RFLP. PON1 enzyme activity was determined according to Eckerson's method. The ratio of MM genotype belonging to PON1 L55M polymorphism in control group was 6.3% and was 7.8% in patients with leukemia (p= 0.39). PON1 enzyme activity was 118.8 +/- 115.1 U/mL in control group, while decreased to 75.6 +/- 64.4 U/mL in patients with leukemia (p= 0.004). PON1 enzyme activities of the individuals with MM genotypes belonging to PON1 L55M polymorphism was 57.43 21.61 U/ mL in control group and decreased to 39.18 +/- 45.61 U/mL in leukemic patients. Our results suggest that, PON1 L55M polymorphism genotype ratios do not affect leukemia development. However, reduced PON1 enzyme activity and also the combination of PON1 L55M polymorphism with reduced PON1 enzyme activity are associated with the increased risk of leukemia. Furthermore, older age may be a risk factor for developing leukemia.
Efficacy and Safety of Ibrutinib Use in Patients With Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study
(Amer Soc Hematology, 2019) Tombak, Anil; Tanrikulu, Funda Pepedil; Durusoy, Salih Sertac; Gurkan, Emel; Kaya, Emin; Umit, Elif G.; Ferhanoglu, Burhan
An Investigation of the Relation Between Catalase C262t Gene Polymorphism and Catalase Enzyme Activity in Leukemia Patients
(Termedia Publishing House Ltd, 2021) Eras, Nazan; Turkoz, Gozde; Tombak, Anil; Tiftik, Naci; Yalin, Serap; Berkoz, Mehmet; Akbas, Etem
Introduction: Catalase (CAT), an antioxidant enzyme, catalyzes conversion of hydrogen peroxide to water and molecular oxygen, protecting cells against oxidative stress. The aim of this study was to investigate the possible association between CAT C262T polymorphism in the promoter region of the CAT gene and leukemia risk and to determine the relationship between CAT genotypes and CAT enzyme activities. Material and methods: Genotypes of 102 cases and 112 healthy controls' genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism methods. Catalase activity was measured with the method of Aebi. Results: The frequencies of the T allele among the cases and controls were 28.4% and 25.9%, respectively (p = 0.75). The frequencies of CC, CT, and TT among cases were 57.8%, 27.4%, and 14.7%, respectively, while in controls, the frequencies of CC, CT, and TT were 54.4%, 39.3%, and 6.3%, respectively, which were not significantly different. Although CAT enzyme activity was lower in leukemia patients with TT genotypes than in controls, this did not reach statistical significance (p = 0.37). Conclusions: This is the first report showing that CAT C262T polymorphism is not a genetic predisposing factor for the risk of leukemia in the Turkish population. However, additional research is needed to confirm these findings.
Therapeutic Plasma Exchange in Patients With Thrombotic Thrombocytopenic Purpura: a Retrospective Multicenter Study
(Pergamon-elsevier Science Ltd, 2013) Korkmaz, Serdal; Keklik, Muzaffer; Sivgin, Serdar; Yildirim, Rahsan; Tombak, Anil; Kaya, Mehmet Emin; Ilhan, Osman
Thrombotic thrombocytopenic purpura (TIT) is a particular form of thrombotic microangiopathy typically characterized by thrombocytopenia, microangiopathic hemolytic anemia, fever, neurological abnormalities, and renal dysfunction. UP requires a rapid diagnosis and an adapted management in emergency. Daily sessions of therapeutic plasma exchange (TPE) remain the basis of management of UP. Also, UP is a rare disease that is fatal if it is not treated. TPE has resulted in excellent remission and survival rates in UP patients. Aim: We aimed to present our experience in 163 patients with UP treated with TPE during the past 5 years from 10 centers of Turkey. Patients and methods: One hundered and sixty-three patients with UP treated with TPE during the past 5 years from 10 centers of Turkey were retrospectively evaluated. TPE was carried out 1-1.5 times plasma volume. Fresh frozen plasma (FFP) was used as the replacement fluid. TPE was performed daily until normalization of serum lactate dehydrogenase (LDH) and recovery of the platelet count to >150 x 10(9)/dL. TPE was then slowly tapered. Clinical data, the number of TPE, other given therapy modalities, treatment outcomes, and TPE complications were recorded. Results: Fifty-eight percent (95/163) of the patients were females. The median age of the patients was 42 years (range; 16-82). The median age of male patients was significantly higher than female (53 vs. 34 years; p < 0.001). All patients had thrombocytopenia and microangiopathic hemolytic anemia. At the same time, 82.8% (135/163) of patients had neurological abnormalities, 78.5% (128/163) of patients had renal dysfunction, and 89% (145/163) of patients had fever. Also, 10.4% (17/163) of patients had three of the five criteria, 10.4% (17/163) of patients had four of the five criteria, and 6.1% (10/163) of patients had all of the five criteria. Primary UP comprised of 85.9% (140/163) of the patients and secondary UP comprised of 14.1% (23/163) of the patients. Malignancy was the most common cause in secondary UP. The median number of TPE was 13 (range; 1-80). The number of TPE was significantly higher in complete response (CR) patients (median 15.0 vs. 3.5; p < 0.001). CR was achieved in 85.3% (139/163) of the patients. Similar results were achieved with TPE in both primary and secondary UP (85% vs. 87%, respectively; p = 0.806). There was no advantage of TPE + prednisolone compared to TPE alone in terms of CR rates (82.1% vs. 76.7%; p = 0.746). CR was not achieved in 14.7% (24/163) of the patients and these patients died of TTP related causes. There were no statistical differences in terms of mortality rate between patients with secondary and primary TIT [15% (21/140) vs. 13% (3/23); p = 0.8061. But, we obtained significant statistical differences in terms of mortality rate between patients on TPE alone and TPE + prednisolone [14% (12/86) vs. 3% (2/67), p < 0.001]. Conclusions: TPE is an effective treatment for UP and is associated with high CR rate in both primary and secondary UP. Thrombocytopenia together with microangiopathic hemolytic anemia is mandatory for the diagnosis of UP and if these two criteria met in a patient, TPE should be performed immediately. (C) 2013 Elsevier Ltd. All rights reserved.